Miconazole for the treatment of vulvovaginal candidiasis. In vitro, in vivo and clinical results. Review of the literature
Issued Date
2023-01-01
Resource Type
ISSN
01443615
eISSN
13646893
Scopus ID
2-s2.0-85152081154
Pubmed ID
37029724
Journal Title
Journal of Obstetrics and Gynaecology
Volume
43
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Obstetrics and Gynaecology Vol.43 No.1 (2023)
Suggested Citation
Regidor P.A., Thamkhantho M., Chayachinda C., Palacios S. Miconazole for the treatment of vulvovaginal candidiasis. In vitro, in vivo and clinical results. Review of the literature. Journal of Obstetrics and Gynaecology Vol.43 No.1 (2023). doi:10.1080/01443615.2023.2195001 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/82710
Title
Miconazole for the treatment of vulvovaginal candidiasis. In vitro, in vivo and clinical results. Review of the literature
Author(s)
Other Contributor(s)
Abstract
At concentrations achieved following systemic administration, the primary effect of imidazoles and triazoles on fungi is inhibition of 14-α-sterol demethylase, a microsomal cytochrome P450 (CYP) enzyme. Imidazoles and triazoles impair the biosynthesis of ergosterol for the cytoplasmic membrane and lead to the accumulation of 14-α-methyl sterols. The synthetic imidazole miconazole is additionally able to increase intracellular reactive oxygen species, at least in part through inhibition of fungal catalase and peroxidase. This unique feature of miconazole is probably the basis for its fungicidal activity in C. albicans, in addition to the fungistatic mode of action. Studies show that miconazole is superior to nystatin treatment and demonstrate its impact as one of the best options in managing vulvovaginal candidiasis. Regarding recurrent vulvovaginal candidiasis, several new drugs are currently developed to ensure effective treatment also for this group of patients.